Literature DB >> 8289076

Cerebral blood flow and oxygen metabolism in progressive dementia associated with amyotrophic lateral sclerosis.

M Tanaka1, S Kondo, S Hirai, X Sun, T Yamagishi, K Okamoto.   

Abstract

We examined regional cerebral blood flow (rCBF) and oxygen metabolism (rCMRO2) in 4 patients with progressive dementia associated with amyotrophic lateral sclerosis (ALS), in 9 patients with classical ALS without dementia, and in 13 normal controls, using positron emission tomography with oxygen-15 gas and oxygen-15 labeled carbon dioxide. The mean rCBF and rCMRO2 in the anterior cerebral hemispheres decreased significantly in patients with progressive dementia with ALS, compared to those in controls. Patients with only ALS showed very mild reductions of rCBF and rCMRO2 which were not statistically significant. These data suggest that hypoperfusion and oxygen hypometabolism in the anterior cerebral hemispheres have an etiological relationship to deterioration of intellect in patients with progressive dementia with ALS. A significant reduction in the mean rCBF was also found in the cerebellar hemispheres in progressive dementia with ALS, while a reduction of mean rCMRO2 was not significant. Remote effects analogous to crossed cerebellar diaschisis occurring bilaterally were assumed to explain the cerebellar hypoperfusion.

Entities:  

Mesh:

Year:  1993        PMID: 8289076     DOI: 10.1016/0022-510x(93)90019-u

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis.

Authors:  P J Massman; J Sims; N Cooke; L J Haverkamp; V Appel; S H Appel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

Review 2.  Cerebellar pathology in motor neuron disease: neuroplasticity and neurodegeneration.

Authors:  Rangariroyashe H Chipika; Grainne Mulkerrin; Pierre-François Pradat; Aizuri Murad; Fabrice Ango; Cédric Raoul; Peter Bede
Journal:  Neural Regen Res       Date:  2022-11       Impact factor: 6.058

3.  Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth.

Authors:  Bettina Schmid; Alexander Hruscha; Sebastian Hogl; Julia Banzhaf-Strathmann; Katrin Strecker; Julie van der Zee; Mathias Teucke; Stefan Eimer; Jan Hegermann; Maike Kittelmann; Elisabeth Kremmer; Marc Cruts; Barbara Solchenberger; Laura Hasenkamp; Frauke van Bebber; Christine Van Broeckhoven; Dieter Edbauer; Stefan F Lichtenthaler; Christian Haass
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-01       Impact factor: 11.205

Review 4.  Neuroimaging biomarkers of neurodegenerative diseases and dementia.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

Review 5.  25 years of neuroimaging in amyotrophic lateral sclerosis.

Authors:  Bradley R Foerster; Robert C Welsh; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2013-08-06       Impact factor: 42.937

Review 6.  Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.

Authors:  Federica Agosta; Daniele Altomare; Cristina Festari; Stefania Orini; Federica Gandolfo; Marina Boccardi; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Flavio Nobili; Zuzana Walker; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-01       Impact factor: 9.236

7.  The use of P300-based BCIs in amyotrophic lateral sclerosis: from augmentative and alternative communication to cognitive assessment.

Authors:  Pietro Cipresso; Laura Carelli; Federica Solca; Daniela Meazzi; Paolo Meriggi; Barbara Poletti; Dorothée Lulé; Albert C Ludolph; Vincenzo Silani; Giuseppe Riva
Journal:  Brain Behav       Date:  2012-07       Impact factor: 2.708

Review 8.  Lessons of ALS imaging: Pitfalls and future directions - A critical review.

Authors:  Peter Bede; Orla Hardiman
Journal:  Neuroimage Clin       Date:  2014-02-27       Impact factor: 4.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.